We next investigated the consequences of epidermal-specific GR and MR loss in psoriasis using the imiquimod (IMQ)-induced protocol which consists in topical repetitive applications of Aldara®, a cream containing 5% of the toll-like receptor 7 (TLR7)-agonist IMQ, which induces histopathological and molecular changes that closely recapitulate the human disease21. The gene discussed is NR3C2; the disease is psoriasis.